OKYO Pharma Chairman Acquires Shares
OKYO Pharma Limited (NASDAQ: OKYO), a biopharmaceutical company currently in the clinical stage, has reported that Panetta Partners Limited, an entity in which Gabriele Cerrone, the Executive Chairman, holds a beneficial interest, has acquired 50,000 ordinary shares of the company on NASDAQ at a price of US$1.05 per share. This purchase raises Mr. Cerrone's total shareholding to 9,721,570 shares, which accounts for 28.73% of the company's issued share capital.
What You Need to Know About OK-101
OK-101 is a cutting-edge lipid-conjugated chemerin peptide agonist designed to target the ChemR23 G-protein coupled receptor located on immune cells in the eye, which play a key role in inflammatory responses. The development of OK-101 utilizes a membrane-anchored-peptide technology, resulting in a long-acting medication specifically formulated to treat dry eye disease (DED). The lipid anchor in OK-101's formulation enhances its effectiveness by improving the drug's retention time within the ocular environment. In both pre-clinical and clinical studies, OK-101 has demonstrated significant anti-inflammatory properties and pain relief in models for dry eye disease and neuropathic corneal pain (NCP), a condition that currently lacks FDA-approved treatments.
About OKYO Pharma Limited
OKYO Pharma Limited (NASDAQ: OKYO) is dedicated to developing therapies for inflammatory dry eye disease and neuropathic corneal pain. The company’s ordinary shares are traded on the NASDAQ Capital Market. OKYO is leading the charge in discovering and developing innovative therapeutics specifically designed for these ocular conditions, underscoring its commitment to addressing substantial unmet medical needs. Following the successful completion of a Phase 2 clinical trial for DED, OKYO is set to launch another Phase 2 trial for OK-101 aimed at treating NCP in affected patients, highlighting the company’s proactive stance in drug development.
Contact Information for OKYO Pharma
For any inquiries, you can reach out to OKYO Pharma Limited using the following contact details:
CEO and General Inquiries
Gary S. Jacob, Chief Executive Officer - 917-497-7560
Business Development & Investor Relations
Paul Spencer - +44 (0)20 7495 2379
Frequently Asked Questions
What does Gabriele Cerrone's share acquisition mean?
This acquisition reflects Gabriele Cerrone's strong belief in the future of OKYO Pharma and its potential for growth, aligning his interests closely with those of the shareholders.
What is OK-101 and its purpose?
OK-101 is a new therapeutic agent aimed at treating inflammatory dry eye disease and neuropathic corneal pain, utilizing advanced drug delivery techniques.
What is the latest on OKYO Pharma's clinical trials?
OKYO Pharma has just wrapped up a Phase 2 trial for DED and is gearing up to start another Phase 2 trial focusing on NCP to further assess the effectiveness of OK-101.
What makes OKYO Pharma unique in the biopharmaceutical sector?
OKYO Pharma distinguishes itself by concentrating on ocular therapies, striving to address the treatment gaps for dry eye disease and neuropathic pain, and tackling significant unmet medical needs through innovative solutions.
How can I find more information about OKYO Pharma?
To learn more about OKYO Pharma and its ongoing therapeutic developments, interested individuals can visit the company’s website.
